Treatment of human thyroid carcinoma cells with the G47delta oncolytic herpes simplex virus

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 3, 2015, Pages 1241-1245

  Wang, Jia Ni ^a   Xu, Li Hua ^b   Zeng, Wei Gen ^a,c   Hu, Pan ^a   Rabkin, Samuel D ^d   Liu, Ren Rin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytotoxicity; Oncolytic herpes simplex virus; Subcutaneous models; Thyroid carcinoma

Indexed keywords

ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; GENE VECTOR; GENETICS; HUMAN; MOUSE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; SIMPLEXVIRUS; THYROID NEOPLASMS; TUMOR CELL CULTURE; TUMOR VOLUME; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; THYROID NEOPLASMS; TUMOR BURDEN; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929334811     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.3.1241     Document Type: Article

References (24)

1. Are C, Shaha AR (2006). Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol, 13, 453-64.
2. Campadelli-Fiume G, De Giovanni C, Gatta V, et al (2011). Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol, 21, 213-26.
3. Goldstein DJ, Weller SK (1988). Factor (s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology, 166, 41-51.
4. Huang YY, Yu Z, Lin SF, et al (2007). Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab, 92, 1965-70.
5. Lai ML, Faa G, Serra S, et al (2005). Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med, 129, 55-7.
6. Li J, Zeng W, Huang Y, et al (2012). Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther, 19, 707-14.
7. Lin SF, Gao SP, Price DL, et al (2008). Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res, 14, 1519-28.
8. Martuza RL, Malick A, Markert JM, et al (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854-6.
9. Mohr I, Sternberg D, Ward S, et al (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol, 75, 5189-96.
10. Pacini F, Castagna MG, Cipri C, et al (2010). Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol), 22, 475-85.
11. Reinblatt M, Pin RH, Fong Y (2007). Herpes viral oncolysis: a novel cancer therapy. J Am Coll Surg, 205, S69-75.
12. Russell SJ, Peng KW, Bell JC (2012). Oncolytic virotherapy. Nat Biotechnol, 30, 658-70.
13. Sherman SI, Wirth LJ, Droz JP, et al (2008). Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med, 359, 31-42.
14. Sipos JA, Mazzaferri EL (2010). Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol), 22, 395-404.
15. Smallridge RC, Ain KB, Asa SL, et al (2012). American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22, 1104-39.
16. Todo T, Martuza RL, Rabkin SD, et al (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA, 98, 6396-401.
17. Vanderpump MP (2011). The epidemiology of thyroid disease. Br Med Bull, 99, 39-51.
18. Varghese S, Rabkin SD (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther, 9, 967-78.
19. Wang J, Hu P, Zeng M, et al (2011a). Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol, 40, 757-63.
20. Wang JN, Hu P, Zeng MS, et al (2011b). Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer, 30, 831-41.
21. Yu Z, Eisenberg DP, Singh B, et al (2004). Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer, 112, 525-32.
22. Zaman M, Fatima N, Sajjad Z, et al (2012). Threshold primary tumour sizes for nodal and distant metastases in papillary and follicular thyroid cancers. Asian Pac J Cancer Prev, 13, 2473-6.
23. Zeng W, Hu P, Wu J, et al (2013a). The oncolytic herpes simplex virus vector G47 effectively targets breast cancer stem cells. Oncol Rep, 29, 1108-14.
24. Zeng WG, Li JJ, Hu P, et al (2013b). An oncolytic herpes simplex virus vector, G47Delta, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep, 29, 2355-61.